These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9681232)

  • 1. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
    Leach M; Parsons RM; Reilly JT; Winfield DA
    Clin Lab Haematol; 1998 Jun; 20(3):169-72. PubMed ID: 9681232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
    Pui CH; Relling MV; Lascombes F; Harrison PL; Struxiano A; Mondesir JM; Ribeiro RC; Sandlund JT; Rivera GK; Evans WE; Mahmoud HH
    Leukemia; 1997 Nov; 11(11):1813-6. PubMed ID: 9369411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of urate nephropathy in the tumour lysis syndrome.
    O'Connor NT; Prentice HG; Hoffbrand AV
    Clin Lab Haematol; 1989; 11(2):97-100. PubMed ID: 2766676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European experience in the treatment of hyperuricemia.
    Patte C; Sakiroglu O; Sommelet D
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):9-12. PubMed ID: 11694946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
    Wu X; Wakamiya M; Vaishnav S; Geske R; Montgomery C; Jones P; Bradley A; Caskey CT
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):742-6. PubMed ID: 8290593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
    Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
    Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pathophysiology, clinical signs and therapy of urate nephropathy].
    Méhes L; Udvardy M; Szász R; Rejto L
    Orv Hetil; 2007 Apr; 148(16):745-8. PubMed ID: 17437951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor lysis syndrome, case report and review of the literature.
    Masera G; Jankovic M
    Ann Oncol; 1997 Jan; 8(1):97. PubMed ID: 9093714
    [No Abstract]   [Full Text] [Related]  

  • 14. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
    Pui CH
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):13-21. PubMed ID: 11694947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH; Mahmoud HH; Wiley JM; Woods GM; Leverger G; Camitta B; Hastings C; Blaney SM; Relling MV; Reaman GH
    J Clin Oncol; 2001 Feb; 19(3):697-704. PubMed ID: 11157020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
    Cammalleri L; Malaguarnera M
    Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
    Calvo-Villas JM; Urcuyo BM; Umpierrez AM; Sicilia F
    Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the management of malignancy-associated hyperuricaemia.
    Mahmoud HH; Leverger G; Patte C; Harvey E; Lascombes F
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):18-20. PubMed ID: 9647616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.